Durect Corp., of Cupertino, Calif., and Pain Therapeutics Inc., of Austin, Texas, were issued four patents relating to their Oradur technology, Remoxy (oxycodone) Extended-Release Capsules CII and other Oradur-based opioids

Indel Therapeutics Inc., of Vancouver, British Columbia, received a patent relating to its antimicrobial drug discovery platform technology...NuPathe Inc., of Conshohocken, Pa., received a notice of allowance for a patent relating to methods of treating a migraine by administering sumatriptan using an iontophoretic patch to achieve consistent therapeutic plasma levels with low patient-to-patient variability

Ensemble Therapeutics Inc., of Cambridge, Mass., received notices of allowance for two patents relating to broad and fundamental aspects of DNA-Programmed Chemistry molecular library construction

Mirna Therapeutics Inc., of Austin, Texas, received a notice of allowance for a patent relating to the therapeutic application of let-7 in the regulation of oncogenes

Aduro BioTech, of Berkeley, Calif., received two patents relating to its live attenuated and "killed by metabolically active" Listeria platforms

Stellar Pharmaceuticals Inc., of London, Ontario, received a notice of allowance for a patent relating to Uracyst, a sterile sodium chondroitin sulfate solution used to treat interstitial cystitis/painful bladder syndrome

PhotoBiotics, of London, received a patent relating to its targeted cancer therapy using its PhotoLink technology for coupling light-activated drugs to antibody fragments

Cannasat Therapeutics, of Toronto, received a notice of allowance for a patent relating to its technology providing for effective drug absorption of dronabinol in the buccal cavity via a tablet

The company also received a notice of allowance for a patent relating to the production of neural stem cells

DelSite Inc., of Irving, Texas, received a notice for allowance for a patent relating to its GelSite polymer technologies

HemoGenix Inc., of Colorado Springs, Colo., received a patent relating to its HALO technology, which the company said is designed as a replacement to the traditional colony-forming cell assay

Borean Pharma ApS, of Aarhus, Denmark, received a notice of allowance in for a patent relating to HIV fusion inhibitors for treating AIDS

Oscient Pharmaceuticals Corp., of Waltham, Mass., received a notice of allowance for a patent relating to methods of use of Ramoplanin for Clostridium difficile-associated disease

Synthecon Inc., of Houston, received a patent relating to a perfused Rotary Cell Culture System

Generex Biotechnology Corp., of Worcester, Mass., said its wholly owned subsidiary, Antigen Express Inc., was awarded two patents relating to its core vaccine technology platform

VASTox plc, of Oxford, UK, was granted a patent relating to its drug discovery program in Duchenne's muscular dystrophy

ValiRx plc, of London, received a patent relating to its gene-silencing technology, GeneICE, which is held by subsidiary Cronos Therapeutics Ltd

Osprey Pharmaceuticals Ltd., of Montreal, was granted three patents relating to its Leukocyte Population Modulator platform: U.S. Patent No

Amedex Therapeutics Inc., of Wilsonville, Ore., was issued a patent relating to its NuBiotics portfolio, anti-infective products targeted to bacterial infections and encompassing antibiotic resistant bacteria, such as methicillin-resistant Staphylococcus aureus, and certain viral indications, including avian influenza, Epstein-Barr virus and hepatitis B and C